MAVENCLAD Drug Patent Profile

Which patents cover Mavenclad, and when can generic versions of Mavenclad launch?

Mavenclad is a drug marketed by Emd Serono Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-three patent family members in fourteen countries.

The generic ingredient in MAVENCLAD is cladribine. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the cladribine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mavenclad

A generic version of MAVENCLAD was approved as cladribine by HIKMA on February 28^th, 2000.

Summary for MAVENCLAD

International Patents:	33
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	12
Drug Prices:	Drug price information for MAVENCLAD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAVENCLAD
What excipients (inactive ingredients) are in MAVENCLAD?	MAVENCLAD excipients list
DailyMed Link:	MAVENCLAD at DailyMed

See drug prices for MAVENCLAD

Recent Clinical Trials for MAVENCLAD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Plymouth	Phase 2/Phase 3
University College, London	Phase 2/Phase 3
University of Leeds	Phase 2/Phase 3

See all MAVENCLAD clinical trials

Pharmacology for MAVENCLAD

Drug Class

Purine Antimetabolite

Paragraph IV (Patent) Challenges for MAVENCLAD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAVENCLAD	Tablets	cladribine	10 mg	022561	1	2022-04-07

US Patents and Regulatory Information for MAVENCLAD

MAVENCLAD is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,533,408
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	10,849,919
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	AB	RX	Yes	Yes	12,539,329

Expired US Patents for MAVENCLAD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	7,888,328
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	8,785,415
Emd Serono Inc	MAVENCLAD	cladribine	TABLET;ORAL	022561-001	Mar 29, 2019	8,377,903

EU/EMA Drug Approvals for MAVENCLAD

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Europe B.V.	Mavenclad	cladribine	EMEA/H/C/004230Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.	Authorised	no	no	no	2017-08-22
Lipomed GmbH	Litak	cladribine	EMEA/H/C/000504Litak is indicated for the treatment of hairy-cell leukaemia.	Authorised	no	no	no	2004-04-14

International Patents for MAVENCLAD

See the table below for patents covering MAVENCLAD around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	113906
Australia	2018372007
Australia	2024227421
Brazil	112020010282
Canada	3083328

Supplementary Protection Certificates for MAVENCLAD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1827461	122018000021	Germany		PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170822
1827461	300930	Netherlands		PRODUCT NAME: CLADRIBINE; REGISTRATION NO/DATE: EU/1/17/1212 20170824
1827461	CR 2018 00010	Denmark		PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824
1827461	2018C/010	Belgium		PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
1827461	1890010-0	Sweden		PRODUCT NAME: CLADRIBINE; REG. NO/DATE: EU/1/17/1212 20170824

MAVENCLAD (cladribine) market dynamics and financial trajectory: revenue drivers, competitor pressure, and exclusivity timetable

Last updated: July 28, 2026

Mavenclad (cladribine tablets, marketed by Merck KGaA in Europe and EMD Serono in the US) is a multiple-sclerosis (MS) disease-modifying therapy built on annual “course” dosing. Sales have grown since launch, then became sensitive to payer contracting, persistence, and channel mix as generic and alternative MS oral and infusion therapies gained share. Financial trajectory is shaped by (1) cohort-based demand tied to annual dosing schedules, (2) sensitivity to new prescriber adoption and switching, and (3) competitive pressure from high-efficacy oral agents and biologics with expanded positioning.

How is MAVENCLAD performing financially since launch?

Answer: Performance is cohort-driven rather than continuous prescriptions. Revenue tracks patient initiation and retention across two short annual treatment courses, with incremental demand from treatment-experienced and treatment-naïve MS segment expansion and market share gains in switching cohorts.

Key market-structure features that drive revenue

Mavenclad’s commercial model produces recognizable financial patterns:

• Cohort conversion cycle: revenue comes in waves when eligible patients start an annual course, then pauses until the next annual course eligibility.
• Persistence is constrained by label design: once patients complete the labeled short-course dosing, ongoing revenue depends on whether they need subsequent labeled re-treatment cycles (per label) and on new patient starts.
• Channel mix matters: payer restrictions, prior authorization, and specialty pharmacy routing can swing quarter-by-quarter net sales even if underlying patient need is stable.

Revenue sensitivity points

• Payer contracting: formulary placement and access terms determine whether patients can initiate early in the annual cycle.
• Switching dynamics: Mavenclad competes for patients who discontinue other oral therapies due to breakthrough disease, tolerability, or convenience.
• Safety and monitoring requirements: lymphocyte monitoring and infection risk management influence prescriber comfort and patient willingness, affecting conversion rates.

Commercial ceiling risks

• Saturation of “annual course” cohorts: once a market stabilizes, net growth depends more on share capture than on market expansion.
• Adverse trend in MS prescribing: shifts toward very high-efficacy regimens reduce the share of patients willing to start Mavenclad, especially when alternatives carry strong efficacy messaging and simpler dosing routines.

What market dynamics shape MAVENCLAD demand in relapsing multiple sclerosis?

Answer: Demand is driven by annual course eligibility in relapsing forms of MS and by competition for treatment-naïve and treatment-experienced switching patients.

Patient segmentation effects

• Treatment-naïve segment: adoption depends on first-line positioning vs platform and high-efficacy oral therapies.
• Treatment-experienced segment: switching and escalation are often driven by disease activity despite prior therapy; Mavenclad’s “short course” dosing is a convenience lever.
• Discontinuation cohorts: patients stop or de-escalate prior agents due to safety, adherence, or disease activity; these cohorts are the main switching engine.

Real-world constraints

• Lymphopenia management: initiation and continuation require routine blood monitoring and infection vigilance.
• Vaccination and infection planning: prescribers build workflows around timing to mitigate risk during and after dosing windows.

How does competition affect MAVENCLAD revenue share and pricing power?

Answer: Competition from oral MS therapies and infusion/biologic options compresses pricing power and raises switching friction by changing the “best convenience” narrative.

Main competitive axes

• Efficacy positioning: newer MS agents with strong annualized relapse reduction claims pull high-activity cohorts toward themselves.
• Dosing simplicity: continuous or infrequent schedules can outperform “course-based with monitoring” in payer and patient preference.
• Safety profile narrative: when competitors are perceived as lower monitoring burden or lower infection risk, initiation conversion improves.

What this means for pricing

• Mavenclad’s net price is heavily dependent on payer rebates and access terms, not list price.
• As formularies add preferred competitors, Mavenclad’s rebates and access concessions typically increase to defend placement.

When does MAVENCLAD lose exclusivity in major markets?

Answer: Exclusivity loss depends on the active ingredient patent expiry schedule, plus regulatory exclusivities and any formulation or method-of-use patent thickets in specific jurisdictions.

Exclusivity concept map for a small-molecule tablet

For cladribine tablets, the practical exclusivity ceiling usually reflects:

• Compound patents (active ingredient)
• Formulation/process patents (tablet composition, manufacturing)
• Method-of-use patents (dosing schedules, patient subsets)
• Regulatory exclusivities (where applicable)
• Biologic-style exclusivity does not apply because cladribine is a small molecule.

No market-by-market expiry dates are provided here because the supporting patent-by-patent and Orange Book-style record for cladribine tablets is not included in the available input.

What generic entry risks exist for MAVENCLAD?

Answer: Generic risk is primarily driven by the status of composition, method-of-use, and process patents, with the additional gating factor being whether biosimilar-style substitution rules are irrelevant (small molecule) and whether remaining method-of-use claims narrow “label-to-label” entry.

Paragraph IV strategy logic

For an ANDA-style path, generic challengers focus on:

• Composition/formulation claim breaks
• Process manufacturability design-arounds
• Method-of-use claim exposure, if dosing regimens remain patent-protected

Practical risk outcomes

• If only narrow method-of-use patents remain, challengers may wait out compound/formulation expiry.
• If broad composition patents remain, generic entry timing is pushed back, and settlements often target date-certain entry triggers.

What is the Orange Book status of MAVENCLAD and how many patents are listed?

Answer: Orange Book status must be derived from the FDA Drugs@FDA and Orange Book listing for cladribine tablets by dosage strength and NDA holder.

No Orange Book listing counts, patent numbers, or listed expiration dates are provided here because the relevant Orange Book dataset is not included in the available input.

What MAVENCLAD formulation and dosing patents matter commercially?

Answer: For a course-based oral MS therapy, the commercial patent stack typically matters most for:

• Tablet composition and excipient system
• Manufacturing process constraints
• Specific dosing schedule claims that map to the annual course approach

Why dosing-schedule claims change entry economics

Even if a generic can make a cladribine tablet, a method-of-use claim that covers the approved schedule can limit “at-risk” launch or drive design-around or carve-out strategies.

How does MAVENCLAD dosing schedule influence payer and pharmacy channel economics?

Answer: Course dosing changes forecasting, inventory cycles, and payer budgeting patterns compared with continuously dosed therapies.

Budget cycle dynamics

• Payers plan around initiation windows rather than steady monthly spend.
• Specialty pharmacies manage short, burst-like fulfillment volumes around dose timing.

Utilization management

• Prior authorization and lymphocyte-based eligibility can create operational friction that slows starts and spreads uptake, affecting near-term revenue even when patient need exists.

What patent litigation or settlements affect MAVENCLAD generic timing?

Answer: Patent litigation timing typically influences whether generics launch on date or after settlements.

No litigation identifiers, case captions, or settlement terms are provided because the required court-document and patent-assertion record is not included in the available input.

How does FDA regulatory status affect MAVENCLAD market access?

Answer: FDA labeling and risk management requirements shape prescribing comfort and payer acceptance, which in turn affects volume and adherence to annual course dosing.

Regulatory adoption drivers

• Clear label eligibility criteria support standardization of prior authorization workflows.
• Safety monitoring requirements create predictable practice patterns, which improves adoption once workflows are established.

How does MAVENCLAD compare with key MS oral competitors on market dynamics?

Answer: Mavenclad competes on convenience of course dosing and monitoring familiarity. Competitors often win on perceived efficacy-at-any-episode, easier patient onboarding, or simpler administration routines.

Commercial comparison dimensions

• Switching: Mavenclad captures patients leaving other oral agents due to efficacy or safety.
• First-line adoption: depends on prescriber preference for high-efficacy vs risk-management tradeoffs.
• Payer position: favored status for competitors can force Mavenclad into less favorable rebate tiers.

What is the likely revenue trajectory under different market scenarios?

Answer: Mavenclad’s trajectory is sensitive to three scenario levers: share retention, access improvement, and switching intensity.

Scenario 1: share retention with stable access

• Continued patient starts sustain revenue, with quarter-to-quarter volatility reflecting annual dosing windows.

Scenario 2: access deterioration

• Lower formulary placement increases prior authorization denials and delays initiation, depressing net sales even if patients remain eligible.

Scenario 3: competitive substitution

• High-efficacy competitors pull high-activity cohorts away, reducing switching inflow and initiation conversion.

No scenario-specific numeric forecasts are provided because the underlying historical financial and market-share inputs are not included in the available input.

Key data points investors typically track for MAVENCLAD

• Patient starts for annual course eligibility
• Persistence/retreatment cycle uptake (where applicable)
• Net-to-gross impact from rebates and contracting
• Gross margin changes driven by access terms and channel mix
• Share of switching cohorts from oral competitor discontinuations

Key Takeaways

• Mavenclad’s commercial model is cohort-based and depends on initiation and retention across annual dosing windows, which makes revenue sensitive to payer contracting and switching volumes.
• Competitive dynamics in relapsing MS shape both pricing power and patient conversion, with newer high-efficacy options altering prescriber choice for high-activity cohorts.
• Exclusivity and generic entry timing depend on the patent stack in composition, formulation/process, and method-of-use claims by jurisdiction. Patent- and Orange Book-derived details are required for date-certain exclusivity timelines and generic risk ranking, but such records are not provided in the available input.

FAQs

1) What drives quarterly net sales volatility for MAVENCLAD?
Course-based initiation windows, payer access timing, and specialty pharmacy routing around annual dose schedules.

2) Does MAVENCLAD compete more for treatment-naïve or treatment-experienced MS patients?
It competes for both, with market dynamics often hinging on switching from other MS therapies when disease activity or tolerability triggers escalation.

3) What payer restrictions commonly influence MAVENCLAD access?
Prior authorization tied to eligibility criteria and operational requirements for lymphocyte monitoring and infection risk management.

4) What are the biggest generic-entry blocking factors for cladribine tablets?
Remaining composition/formulation/process and any method-of-use claims that map to the approved dosing schedule.

5) How should investors interpret changes in MAVENCLAD uptake when competitors launch new MS therapies?
As signal of switching intensity and first-line positioning shifts, not just changes in total MS incidence or prevalence.

---

References

1. FDA. Drugs@FDA database (MAVENCLAD, cladribine tablets).
2. FDA. FDA Orange Book database (cladribine tablets).
3. EMA. Product information for Mavenclad (cladribine).
4. EMA. EPAR for Mavenclad (cladribine).

DrugChatter Q&A for MAVENCLAD

Mavenclad patent expiry date?
Mavenclad anda litigation?
When does mavenclad patent expire for ms?
Drug patent expiration database mavenclad?
When will mavenclad patent expire?